BioLeaders Applies for Domestic Phase 2 Clinical Trial Plan of COVID-19 Treatment Substance

[Asia Economy Reporter Kum Boryeong] BioLeaders announced on the 20th that it has applied to the Ministry of Food and Drug Safety for a Phase 2 clinical trial plan to evaluate the efficacy and safety of BLS-H01 in patients with mild to moderate COVID-19.

The trial will be conducted as a multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical study. The minimum number of participants required for the clinical trial is a total of 40.

BioLeaders stated, "BLS-H01 functions as an immunomodulator that enhances antiviral innate immunity," and added, "We expect this clinical trial to demonstrate therapeutic effects in alleviating symptoms in COVID-19 patients."